Diffuse Large B-cell Lymphoma Therapeutics Market Size Insights 2022

Major Players in the global diffuse large b-cell lymphoma therapeutics market 2022-2029 include F. Hoffmann-La Roche Ltd, Novartis AG, Celltrion, Karyopharm Therapeutics, Kite Pharma, MorphoSys AG, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical, Spectrum Pharmaceuticals, AbbVie, CTI BioPharma, Seattle Genetics, TG Therapeutics

F. Hoffmann-La Roche Ltd

• Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.
• Roche operates differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience.
• The company is a global leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
• Its personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.
• Thirty-two medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
• In 2019 Roche invested more than 11 billion Swiss francs in R&D and posted sales of approximately 60 billion Swiss francs.

Novartis AG

• Novartis AG develops, manufactures, and markets healthcare products.
• The company mainly operates through three business segments: Innovative Medicines, Alcon, Sandoz, and Corporate
• The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics
• Novartis products reach nearly 800 million people globally.

Celltrion

• Celltrion is a major player in the Korean pharmaceutical industry. The company launched the world’s first antibody biosimilar.
• The comapny is responsible for the global marketing, sales, and distribution of Celltrion's biological medicines.
• The company operates business through the Biopharmaceuticals, Chemical Drugs, and Others segments. 
• Remsima and biosimilars are among the products the company manufactures.
• The company offers biopharmaceutical, generic pharmaceutical products and test kits.
• In 2017, Celltrion received EMA approval for Truxima, a blood cancer biosimilar. 

Karyopharm Therapeutics

• Karyopharm Therapeutics is an innovative pharmaceutical company whose core technology uses nuclear export inhibition as a mechanism to treat cancer and other medical conditions. 
• The company's novel approach to cancer treatment involves targeting the export of specific proteins in a cancer cell's nucleus with SINE technology.
• Karyopharm Therapeutics develops small molecule drugs that target the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and the cytoplasm, to modulate the activity of critical pathways in cancer inflammation and cell proliferation.
• The pharmaceutical company is developing an orally administered drug for patients with certain blood and solid tumor cancers. 

Kite Pharma

• Kite Pharma is a biotechnology company based in the United States that specializes in cancer immunotherapy, with a primary focus on genetically engineered autologous T cell therapy with chimeric antigen receptors. 
• The company's primary focus is on engineered cell therapies based on chimeric antigen receptors and T cell receptors. 
• YESCARTA (axicabtagene ciloleucal), the company's lead product candidate, is a treatment for non-Hodgkin lymphoma. Another candidate, TECARTUS (Brexucabtagene Autoleucel), is a mantle cell lymphoma treatment.
• The company focuses on therapeutic areas such as  hematological malignancies, solid tumors and  allogeneic technology
• On August 28, 2017, Gilead Sciences acquired Kite Pharma.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com